Cocrystal Pharma, Inc. key statistics and ratios

In fiscal 2020, Cocrystal Pharma, Inc. had return on equity of -24.7% and a net margin of -479.0%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cocrystal Pharma, Inc.: financial ratios, annual
Fiscal year	2011Dec 2011	2019Dec 2019	2020Dec 2020
Net margin	−42.9%	−733.8%	−479.0%
Return on equity	—	—	−24.7%
Return on assets	−72.3%	−267.0%	−23.3%
R&D as % of revenue	3.3%	61.0%	299.6%

US$ thousands unless shown otherwise. Fiscal quarters.

Cocrystal Pharma, Inc.: financial ratios, quarterly
Quarter	2019 Q3Sept 2019	2019 Q4Dec 2019	2020 Q1Mar 2020	2020 Q2Jun 2020	2020 Q3Sept 2020	2020 Q4Dec 2020	2026 Q1Mar 2026	2026 Q2Jun 2026
Net margin	−361.8%	<−999%	−431.7%	−630.9%	−546.0%	−292.7%	<−999%	<−999%
R&D as % of revenue	218.9%	238.3%	278.3%	356.7%	424.7%	136.9%	609.3%	>999%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cocrystal Pharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cocrystal Pharma, Inc.